<DOC>
	<DOCNO>NCT01172418</DOCNO>
	<brief_summary>The purpose present study determine antibody induction regimen result safer effective method use steroid avoidance renal transplant recipient . Patients receive either first cadaveric non-HLA identical living donor kidney transplant preoperatively randomize 2 group .</brief_summary>
	<brief_title>Randomized Trial 2 Antibody Induction Steroid Avoidance Protocols</brief_title>
	<detailed_description>Antibody Induction : Group I : Our standard steroid avoidance protocol , i.e. , 3 daily dos 1 mg/kg Thymoglobulin® , first infuse surgery , accompany 2 dos anti-CD25 humanized monoclonal antibody , first also give surgery , second 2 week later . ( control ) Group II : A new steroid avoidance protocol 1 dose 1 mg/kg Thymoglobulin® infuse surgery follow 1 dose alemtuzumab ( Campath-1H ) 0.3 mg/kg within 24 hour . No antibody therapy use . In group , Prograf® maintenance therapy rapidly initiate ( vide-infra ) target dosage 12 hour trough level 4 8 ng/ml . In Group I , maintenance dose Myfortic® target 720 mg twice daily . In Group II , maintenance dos Myfortic® target 360 mg twice daily . Steroids give equivalently group first week postoperatively . The regimen consist 500 mg/day Solumedrol intravenously 3 postoperative day follow daily oral methylprednisolone IV Solumedrol 1 mg/kg per day , decrease 0.5 mg/kg per day remainder week primarily avoid hypersensitivity reaction induction antibody . No steroid use plan .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>1 . Patient fully inform sign date IRB approval inform consent form willing follow study procedure extent study ( 12 month ) . Parent legal guardian must provide write consent patient &lt; 18 year age . 2 . Age 1870 year 3 . Weight &gt; 40 kg 4 . Primary renal allograft : living decease donor 5 . Negative standard crossmatch T cell . All decease donorrecipient pair match minimum 1 HLA DR antigen . ( Standard center . ) 6 . Women childbearing potential require negative qualitative serum pregnancy test agree use adequate method contraception study duration . 7 . Males female study equivalently become available transplantation use criterion . 1 . Patient previously receive receive organ transplant kidney . 2 . Patient receive ABO incompatible donor kidney . 3 . Recipient donor seropositive human immunodeficiency ( HIV ) , Hepatitis C virus , Hepatitis B virus antigenemia . 4 . Patient current malignancy history malignancy ( within past 5 year ) , except nonmetastatic basal squamous cell carcinoma skin treat successfully , carcinoma situ cervix treat successfully . 5 . Patients significant liver disease , define past 28 day continuously elevate AST ( SGOT ) and/or ALT ( SGPT ) level great 3 time upper value normal range center . 6 . Patient uncontrolled concomitant infection and/or severe diarrhea , vomit , active upper gastrointestinal tract malabsorption active peptic ulcer unstable medical condition could interfere study objective . 7 . Patient currently participate another clinical trial investigational drug 30 day prior transplant . 8 . Patient receive immunosuppressive agent prescribe study . 9 . Patient unable take medication orally via nasogastric tube morning second day follow completion transplant procedure ( i.e. , skin closure ) . 10 . Patient receiving may require warfarin , fluvastatin , herbal supplement study . 11 . Concurrent use astemizole , pimozide , cisapride , terfenadine , ketoconazole . 12 . Patient known hypersensitivity tacrolimus , Thymoglobulin® , IL2 receptor inhibitor monoclonal antibody , alemtuzumab , sirolimus , MMF , Myfortic® , corticosteroid . 13 . Patient pregnant lactating . 14 . Patients screening/baseline ( within 96 hour transplant ) total white blood cell count &lt; 4000/mm3 ; platelet count &lt; 100,000/mm3 ; fast triglyceride &gt; 400 mg/dl ( &gt; 4.6 mmol/L ) ; fast total cholesterol &gt; 300 mg/dl ( &gt; 7.8 mmol/L ) ; fast HDLcholesterol &lt; 30 mg/dl ; fast LDLcholesterol &gt; 200 mg/dl . 15 . Patient unlikely comply visit schedule protocol . 16 . Patient form substance abuse , psychiatric disorder condition , opinion investigator , may invalidate communication investigator . 17 . If tacrolimus institute longer 5 day postoperatively .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>adult</keyword>
	<keyword>primary kidney transplant recipient</keyword>
</DOC>